Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NVCR – NovoCure Limited

NovoCure Limited
NVCR
$18.29
Name : NovoCure Limited
Sector : Healthcare
Industry: Medical Devices
Mark. Cap: $2,039,079,040.00
EPSttm : -1.51
finviz dynamic chart for NVCR
NovoCure Limited
$18.29
1.61%
$0.29

Float Short %

5.01

Margin Of Safety %

Put/Call OI Ratio

0.13

EPS Next Q Diff

-0.12

EPS Last/This Y

-0.09

EPS This/Next Y

-0.1

Price

18.01

Target Price

32.57

Analyst Recom

1.57

Performance Q

-5.11

Relative Volume

2.89

Beta

0.72

Ticker: NVCR




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02NVCR17.020.090.4021863
2025-06-03NVCR17.060.100.2823216
2025-06-04NVCR16.730.110.0223524
2025-06-05NVCR16.440.100.1423818
2025-06-06NVCR16.980.100.4324220
2025-06-09NVCR16.890.120.2325023
2025-06-10NVCR18.380.110.0324990
2025-06-11NVCR17.440.110.0425108
2025-06-12NVCR18.20.110.0725587
2025-06-13NVCR17.540.110.1526089
2025-06-16NVCR17.910.110.1226326
2025-06-17NVCR17.420.110.0126425
2025-06-18NVCR16.780.110.3126632
2025-06-20NVCR16.690.111.0327284
2025-06-23NVCR16.620.120.1719106
2025-06-24NVCR16.990.120.1719322
2025-06-25NVCR17.330.121.0319616
2025-06-26NVCR17.10.130.1119895
2025-06-27NVCR18.010.130.1019906
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02NVCR17.02-25.8-57.9-1.65
2025-06-03NVCR17.04-25.8-82.8-1.65
2025-06-04NVCR16.71-25.8-77.9-1.65
2025-06-05NVCR16.45-25.8-78.7-1.65
2025-06-06NVCR17.01-25.8-90.2-1.65
2025-06-09NVCR16.90-25.8-81.0-1.65
2025-06-10NVCR18.39-25.8-102.4-1.65
2025-06-11NVCR17.36-25.8-69.9-1.65
2025-06-12NVCR18.20-25.8-93.3-1.65
2025-06-13NVCR17.53-25.8-74.1-1.65
2025-06-16NVCR17.91-25.8-87.0-1.65
2025-06-17NVCR17.42-25.8-76.3-1.65
2025-06-18NVCR16.80-25.8-74.2-1.65
2025-06-20NVCR16.69-25.8-80.8-1.65
2025-06-23NVCR16.59-25.8-81.0-1.65
2025-06-24NVCR17.00-25.8-87.6-1.65
2025-06-25NVCR17.33-25.8-86.7-1.65
2025-06-26NVCR17.10-25.8-79.5-1.65
2025-06-27NVCR18.01-25.8-94.4-1.65
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02NVCR-0.364.065.45
2025-06-03NVCR-0.364.065.45
2025-06-04NVCR-0.674.065.45
2025-06-05NVCR-0.674.065.45
2025-06-06NVCR-0.674.065.45
2025-06-09NVCR-0.674.135.45
2025-06-10NVCR-0.674.135.45
2025-06-11NVCR-0.674.134.68
2025-06-12NVCR-0.654.134.70
2025-06-13NVCR-0.654.134.70
2025-06-16NVCR-0.654.134.70
2025-06-18NVCR-0.654.134.70
2025-06-20NVCR-0.654.134.70
2025-06-23NVCR-0.654.054.70
2025-06-24NVCR-0.654.054.70
2025-06-25NVCR-0.654.054.70
2025-06-26NVCR-0.654.055.01
2025-06-27NVCR-0.654.055.01
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.31

Avg. EPS Est. Current Quarter

-0.39

Avg. EPS Est. Next Quarter

-0.43

Insider Transactions

-0.65

Institutional Transactions

4.05

Beta

0.72

Average Sales Estimate Current Quarter

153

Average Sales Estimate Next Quarter

156

Fair Value

Quality Score

31

Growth Score

43

Sentiment Score

44

Actual DrawDown %

92.3

Max Drawdown 5-Year %

-95.1

Target Price

32.57

P/E

Forward P/E

PEG

P/S

3.23

P/B

5.54

P/Free Cash Flow

EPS

-1.51

Average EPS Est. Cur. Y​

-1.65

EPS Next Y. (Est.)

-1.75

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-26.41

Relative Volume

2.89

Return on Equity vs Sector %

-69.3

Return on Equity vs Industry %

-63.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-94.4
NovoCure Limited
Sector: Healthcare
Industry: Medical Devices
Employees: 1488
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
stock quote shares NVCR – NovoCure Limited Stock Price stock today
news today NVCR – NovoCure Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch NVCR – NovoCure Limited yahoo finance google finance
stock history NVCR – NovoCure Limited invest stock market
stock prices NVCR premarket after hours
ticker NVCR fair value insiders trading